Geron Corporation Amends Loan Agreement, Restructures Operations, and Eyes 2026 Growth

Geron Corporation (GERN) has amended its loan agreement with Biopharma Credit Investments and BPCR Limited Partnership, securing up to $250 million in financing. The company is streamlining operations, cutting 85 positions, and focusing on US sales of Rytelo (imetelstat) in LR-MDS and Phase 3 IMpactMF trial in myelofibrosis. Despite stagnant Rytelo sales, analysts expect expenses to decline in 2026 and profitability by the second half of the year. Geron maintains strong financial flexibility with a current ratio of 5.96.